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Background: Traditional Uighur medicine shares an origin with Greco-Arab medicine. It describes the health of a
human body as the dynamic homeostasis of four normal Hilits (humours), known as Kan, Phlegm, Safra, and Savda.
An abnormal change in one Hilit may cause imbalance among the Hilits, leading to the development of a syndrome.
Abnormal Savda is a major syndrome of complex diseases that are associated with common biological changes during
disease development. Here, we studied the protein expression profile common to tumour patients with Abnormal Savda
to elucidate the biological basis of this syndrome and identify potential biomarkers associated with Abnormal Savda.
Methods: Patients with malignant tumours were classified by the diagnosis of Uighur medicine into two
groups: Abnormal Savda type tumour (ASt) and non-Abnormal Savda type tumour (nASt), which includes other
syndromes. The profile of proteins that were differentially expressed in ASt compared with nASt and normal
controls (NC) was analysed by iTRAQ proteomics and evaluated by bioinformatics using MetaCore™ software and
an online database. The expression of candidate proteins was verified in all plasma samples by enzyme-linked
immunosorbent assay (ELISA).
Results: We identified 31 plasma proteins that were differentially expressed in ASt compared with nASt, of which
only 10 showed quantitatively different expression between ASt and NC. Bioinformatics analysis indicated that
most of these proteins are known biomarkers for neoplasms of the stomach, breast, and lung. ELISA detection
showed significant upregulation of plasma SAA1 and SPP24 and downregulation of PIGR and FASN in ASt
compared with nASt and NC (p < 0.05).
Conclusions: Abnormal Savda may be causally associated with changes in the whole regulation network of
protein expression during carcinogenesis. The expression of potential biomarkers might be used to distinguish
Abnormal Savda from other syndromes.
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In Hippocratic Corpus (c.410 to c.360 B.C.), the earliest
texts of Greco-Arab medicine, Hippocrates used the
words carcinos (crab) or carcinoma to describe a range
of tumours and swellings caused by the excess of Black
Bile, an opinion further developed by Claudius Galenus
(c.200 A.D.) [1]. Traditional Uighur medicine shares an
origin with Greco-Arab medicine, and describes the
health of a human body as the dynamic homeostasis of
four normal Hilits known as Kan, Phlegm, Safra, and
Savda, which correspond to Blood, Phlegm, Yellow Bile,
and Black bile in Greco-Arab medicine [2]. Imbalance of
this homeostasis as a result of abnormal changes in any
Hilit leads to the development of a corresponding syn-
drome coupled with different diseases [2,3]. Among
these, Abnormal Savda (or abnormal Black Bile) is the
predominant syndrome [3]. Long-term studies have
established Abnormal Savda as the main syndrome of
patients with various diseases, such as malignant tumours,
type 2 diabetes mellitus, neurodegenerative diseases, de-
pression, and cardiovascular diseases—conditions generally
considered complex diseases in modern medicine (data not
shown). Through a series of studies on Abnormal Savda
from different aspects, including genetic susceptibility,
metabolomics, the neuroendocrine–immunity network,
oxidative stress, and pre-thrombotic state, we have demon-
strated that Abnormal Savda is associated with common
biological changes in different diseases that are manifested
relatively consistently and holistically within a population
[4-14]. The treatment of Abnormal Savda in patients
with its unique prescription, a prescription composed of
Abnormal Savda Munziq and Abnormal Savda Mushil, is
well established in the clinical practice of Uighur Medicine
[15]. Abnormal Savda Munziq may modulate the abnor-
mal changes in the neuroendocrine–immunity network
associated with Abnormal Savda, and prevent cells from
carcinogenesis and oxidative damage [16-21]. Flavonoids
isolated from Abnormal Savda Munziq may induce cell
cycle arrest and cellular apoptosis of tumour cells [22-24].
These findings provide evidence for the biological basis of
Savda (Black Bile), which is altered with the develop-
ment of Abnormal Savda and restored by treatment with
Abnormal Savda Munziq and Abnormal Savda Mushil.
Protein expression, the final stage of gene expression,
changes dynamically in a spatiotemporal manner and
varies with post-translational processing and chemical
modifications. Recent advances in the study of malignant
tumours by plasma-based proteomics have led to a bet-
ter understanding of the regulatory network of plasma
proteins that are altered with carcinogenesis and the
identification of plasma protein markers for early diag-
nosis, prognosis, and treatment monitoring of malignant
tumours of the stomach, lung, breast, colon, uterine cer-
vix, and ovary [25-31]. These and other studies suggestthat abnormal changes in plasma protein levels are asso-
ciated with the overall pathologic state of tumour pa-
tients. This holistic concept of understanding tumour
aetiology through systems biology is shared by the theor-
ies of traditional Uighur medicine.
In this study we investigated the profile of proteins
that were differentially expressed in the plasma of pa-
tients with malignant tumour with Abnormal Savda
compared with patients diagnosed with other syndromes
in Uighur medicine using iTRAQ proteomics, bioinfor-
matics, and quantitative verification, to elucidate the bio-
logical basis of Abnormal Savda and identify potential
biomarkers. The findings of this study will contribute to
the diagnosis of this syndrome and to monitoring the
clinical treatment of malignant tumours using traditional
Uighur medicines.
Methods
Diagnosis by Uighur medicine
The study design was approved and monitored by the
Ethical Committee of the Hospital of Traditional Chinese
Medicine affiliated to Xinjiang Medical University in
Urumqi, China. All procedures of the study were followed
in accordance with the Helsinki Declaration of 1975, as re-
vised in 2000 (5). Informed consent was obtained from all
donors, and the data were analysed anonymously through-
out the study. Patients with breast, lung, and gastric can-
cer and healthy volunteers were enrolled in the study
according to the diagnostic criteria of the World Health
Organization and the Chinese Medical Association. The
Abnormal Hilit (syndrome) type of each tumour pa-
tient, i.e., Abnormal Phlegm, Safra, Kan, or Savda, was
defined by clinical diagnoses by two independent physi-
cians of Uighur medicine according to established stand-
ard criteria that are described elsewhere in detail [15].
Subsequently, the patients were divided into either
Abnormal Savda type tumour (ASt) or non-Abnormal
Savda type tumour (nASt), which includes patients with
other syndromes such as Abnormal Kan, Phlegm, or
Safra. In addition, the classification was further defined
for each patient by the assessment of symptom scores for
Abnormal Savda, such as slow pulse, bleary eyes, dark-
purple lips, blue tongue, cool skin temperature, dreams
(or nightmares), night sweating, turbid urine, and dry
stool.
Clinical samples
Blood samples (2 mL) were obtained from each donor
by venipuncture into evacuated blood collection tubes
containing EDTA as an anticoagulant, and plasma samples
separated by centrifugation were preserved at −80°C.
Blood samples were collected from 136 tumour patients
who met the inclusion criteria before any clinical therapy.
Fifty age- and sex-matched healthy individuals were
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check-ups in the hospital.
Enrichment of low-abundance proteins
Plasma samples from 76 patients and 20 healthy individ-
uals were subjected to proteomics analysis. The samples
from patients with malignant tumours were divided into
six subgroups representing three cancer types with fur-
ther classification of patients as ASt or nASt as follows:
27 gastric cancer patients with 17 cases of ASt and 10
cases of nASt; 24 lung cancer patients with 14 cases of
ASt and 10 cases of nASt; and 25 breast cancer patients
with 13 cases of ASt and 12 cases of nASt. In addition,
20 normal controls were divided into two groups, with
10 cases in each. The samples from individuals in each
group were mixed in equal volumes to form a pooled
sample for further testing. Pooled samples were enriched
for low-abundance proteins by depletion of medium-
and high-abundance proteins using a prepacked 1-mL
affinity LC column provided with the ProteoMiner™
Protein Enrichment Kit (Bio-Rad Laboratories, Richmond
City, CA, USA) according to the manufacturer’s recom-
mended procedure. After enrichment, the precipitated pro-
teins were dissolved in 300 μL lysis buffer (6 M urea, 4%
CHAPS, 1 mM PMSF, and 2 mM EDTA).
Tryptic digestion and iTRAQ reagent labelling
After reduction (10 mM DTT, 100 mM NH4HCO3; 56°C
for 45 min) and alkylation (55 mM IAA, 100 mM
NH4HCO3 for 45 min), the samples were precipitated in
80% acetone at −20°C overnight and resuspended in 0.8 M
urea and 500 mM TEAB (pH 8.5). Each protein sample
(30 μg) was digested with trypsin (protein:trypsin = 30:1)
in dissociation buffer (0.1% in TEAB; 37°C for 24 h). The
tryptic peptides were labelled with 8-plex iTRAQ reagents
(AB Sciex, Foster City, CA, USA) according to the manu-
facturer’s protocol (iTRAQ113, 114, 115, 116, 117, and 118
for six subgroups of malignant tumours, 119 and 121 for
two subgroups of normal controls). The reaction solvents
were removed by speed vacuum, and the labelled peptides
were dissolved in 20 mM NH4FA (pH 10) for further
analysis.
Peptide fractionation by strong cation exchange
chromatography and C18 column RP chromatography
High-resolution strong cation exchange chromatography
was used to remove the redundant iTRAQ reagents and
any interfering substances that might affect MS analysis.
Labelled peptides were loaded onto an SCX column
(Luna SCX, 4.6 mm × 250 mm, Phenomenex, CA, USA),
and eluted by a stepwise linear elution program as follows:
0–10 min equilibration in Buffer A (25% ACN, 20 mM
KCl, and 10 mM KH2PO4, pH 3.0), 10–15 min fast elution
with 0–5% Buffer B (25% ACN, 1 M KCl and 10 mMKH2PO4, pH 3.0), 15–50 min linear elution with 5–30%
Buffer B, and 50–55 min washing elution with 30–80%
Buffer B. For desalting and further fractionation, the pep-
tide fractions were loaded onto a RP column (Luna C18,
4.6 mm inner diameter × 250 mm length, Phenomenex,
CA, USA), and eluted by a step linear elution program
as follows: 0–10 min equilibration in 100% solution A
[2% acetonitrile (ACN) and 20 mM NH4FA, pH 10],
10–15 min fast elution with 0–12% solution B (80%
ACN and 20 mM NH4FA, pH 10), 15–50 min linear
elution with 12–56% solution B, and 50–55 min wash-
ing elution with 56–80% solution B. All of the proce-
dures were performed using a Prominence HPLC system
(Shimadzu, Nakagyo-ku, Kyoto, Japan) with a flow rate of
1.0 mL/min and the peptides were monitored at 214 nm.
The fractioned peptides were collected at a rate of one
tube/min during the linear elution period.
Peptide analysis by nano-liquid chromatography coupled
with Q-exactive mass spectrometry
The peptide fractions were loaded onto a nano RP col-
umn (5 μm Hypersil C18, 75 μm × 100 mm, Thermo
Fisher Scientific Inc., Waltham, MA, USA) mounted in a
Prominence Nano HPLC system (Shimadzu, Nakagyo-ku,
Kyoto, Japan). The peptides were eluted with an ACN-
gradient from 5–40% containing 0.1% formic acid for
65 min at 400 nL/min. The eluates were transferred to
Q-Exactive MS (Thermo Fisher Scientific Inc., Waltham,
MA, USA ), which was run in positive ion mode and a
data-dependent manner with full MS scan from 350–
6000 m/z, resolution at 70,000, MS/MS scan with mini-
mum signal threshold 17500, and isolation at 2 Da. To
evaluate the performance of the mass spectrometry on
iTRAQ-labelled samples two MS/MS acquisition modes,
higher collision energy dissociation (HCD) and collision
induce dissociation (CID), were employed. To optimize
the MS/MS acquisition efficiency of HCD, normalized
collision energy (NCE) was systemically examined from
25–70%.
Database search and quantitative data analysis
The raw MS/MS data were converted into MGF for-
mat using Proteome Discoverer 1.3 (Thermo Fisher
Scientific). The exported MGF files were searched by
Mascot 2.3 (Matrix Science, Boston, MA, USA) against
the Uniprot Human 2009–12 database with a precursor
mass tolerance set at 15 ppm and product ion tolerance
of 0.02 Da. An automatic decoy database search was
performed. Carbamidomethylation of cysteines was set
as a fixed modification (C), and oxidation of methio-
nines (M), Gln to pyro-Glu (N-term Q), and 8-plex
iTRAQ modifications of N-term, K, and Y were considered
variable modifications. A maximum of one miscleavage
was accepted.
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discovery rate (FDR) <0.01 qualified for further quantifi-
cation analysis. The fold change in protein abundance
was defined as the median ratio of all significantly
matched spectra with tag signals. Based on analysis by
Proteome Discoverer software, the CV distribution of all
quantified proteins and the quantitative results derived
from duplicated injections were compared in parallel.
The differential expression of all proteins was presented
as fold change in iTRAQ ratios. The upregulation of a
protein was presented by fold change of at least or more
than 1.2 times, and the downregulation by fold change
of at least or less than 0.80.
Bioinformatics analysis by MetaCore™ software
The differentially expressed proteins were further char-
acterized using the software package MetaCore™ 6.18
(http://thomsonreuters.com/metacore, Thomson Reuters)
and its online database (https://portal.genego.com) to
understand the underlying pathways and protein–protein
interaction networks and evaluate the candidate proteins
as potential biomarkers.
Verification analysis by ELISA
The plasma level of candidate proteins was verified on
plasma samples from all patients and controls by enzyme-
linked immunosorbent assay (ELISA) using commercially
available ELISA reagents (USCN Life Science Inc., Wuhan
City, China) according to the manufacturer’s instructions.
The final data were confirmed by three independent mea-
surements of each plasma protein.
Statistical analysis
Statistical analysis was performed with SPSS 17.0 for
Windows (SPSS Inc, Chicago, IL, USA). Differences
were considered statistically significant at p < 0.05. Data
derived from the ELISA experiment representing the
protein expression levels of different groups were com-
pared using a one-way ANOVA test.
Results
Identification of protein expression profile common to
tumour patients with Abnormal Savda by Nano-LC
coupled with Q-exactive MS
In this study, patients with malignant tumour were clas-
sified as either ASt or nASt by diagnosis of Uighur
medicine. After the preparation of pooled samples for
ASt, nASt, and NC subjects, depletion of high-abundance
proteins, enzymatic digestion, and labelling of peptides
with iTRAQ reagents, the peptide samples were simultan-
eously analysed by nanoLC coupled with Q-Exactive MS.
This resulted in output of peptide spectra with 95% confi-
dence representing the relative and absolute quantitation
of pooled samples.For analysis of proteomic profiles common to ASt,
nASt or NC, we combined the peptide spectra data of
pooled samples regardless of tumour type using a func-
tional module of the software Proteome Discoverer.
Analysis of peptide spectra setting ≥1.2-fold change as
the cutoff for quantitative differences identified 75 and
74 proteins that were differentially expressed in ASt and
nASt, respectively, compared with NC. Among them,
34 proteins were upregulated and 26 proteins were
downregulated in both ASt and nASt (Additional file 1).
This indicates that tumour conditions in both ASt and
nASt backgrounds are associated with an aberrantly reg-
ulated network of protein expression that is common to
different types of tumours. Subsequent quantitative ana-
lysis identified a profile of 31 proteins that were differen-
tially expressed between ASt and nASt (Table 1). Analysis
of this profile for three cancer types (lung, breast, or gastric
cancer) showed that most of these proteins were differen-
tially expressed between ASt and nASt in each cancer type
(data not shown). However, among these proteins only 10
were differentially expressed in ASt compared with NC, in-
cluding upregulation of polymeric immunoglobulin recep-
tor (PIGR), serum amyloid A protein 1 (SAA1), secreted
phosphoprotein 2 of 24 kDa (SPP24), orosomucoid 1
(ORM1), lipopolysaccharide-binding protein (LBP), SCAN
domain containing 3 (ZNF452/SCAND3), and fatty acid
synthase (FASN), and the downregulation of throm-
bospondin 1 (THBS1) and hyaluronoglucosaminidase 1
(HYAL1) (Table 1). Notably, only three proteins (FASN,
LBP and THBS1), all of which were among the proteins
differentiating ASt from NC, were differentially expressed
in nASt compared with NC.
Evaluation of the role and impact of candidate proteins in
tumourigenesis by MetaCore™ software and an online
database
The role of the 31 identified proteins that differentiate
ASt from nASt in disease development or tumourigen-
esis was further evaluated by bioinformatics analysis
using MetaCore™ software (version 6.16) and an online
database (http://www.genego.com). Gene Ontology ana-
lysis showed that most of these proteins are localized in
the extracellular space, and only small proportions are
present at the membrane or in the cytoplasm. These
proteins are main players in protein binding or function
in the negative regulation of endopeptidase or phospho-
lipase activity, positive regulation of macrophage or
platelet activation, and the regulation of acute-phase and
inflammatory responses (Figure 1). Some proteins are
important regulators of signalling networks or pathways,
such as blood coagulation, immune response by multiple
TLR signalling, regulation of glucose and lipid metabol-
ism, cell adhesion, transcriptional regulation, or function
as effectors in receptor signalling (data not shown).
Table 1 Identification of differentially expressed proteins between ASt and nASt by iTRAQ-based proteomics
No Protein information Peptide detection Fold changea
Rec. protein name Uniprot
ID







1 Polymeric immunoglobulin receptor P01833 PIGR 83 29.78 1.05 1 3.628 3.002 n.d.
2 Serum amyloid A protein 1 P02735 SAA1 14 409.61 54.1 6 3.201 3.023 n.d.
3 Heat shock 60 kDa protein 1 P10809 HSPD1 61 65.56 3.66 1 2.313 n.d. n.d.
4 Orosomucoid P02763 ORM1 24 72.88 18.91 3 1.884 1.233 n.d.
5 SCAN domain containing 3 Q6R2W3 ZNF452 152 13.59 0.38 1 1.629 1.424 n.d.
6 DEAD box polypeptide 41 Q9UJV9 DDX41 70 32.35 0.96 1 1.479 n.d. n.d.
7 Serpin peptidase inhibitor, antityripsin member 3 P01011 SERPINA3 48 160.91 10.4 4 1.464 n.d. n.d.
8 Serum amyloid A-4, constitutive P35542 SAA4 15 103.51 21.54 3 1.452 n.d. n.d.
9 Fatty acid synthase P49327 FASN 273 30.66 0.52 1 1.417 2.308 1.675
10 Inter-alpha-trypsin inhibitor heavy chain H3 Q06033 ITIH3 100 139.48 5.84 5 1.364 n.d. n.d.
11 Alpha-1B-glycoprotein P04217 A1BG 54 157.16 13.74 6 1.348 n.d. n.d.
12 Lipopolysaccharide binding protein P18428 LBP 53 437.6 22.04 9 1.336 1.793 1.345
13 Retinol binding protein 4 P02753 RBP4 23 48.89 4.98 1 1.276 n.d. n.d.
14 Ribosomal protein S6 P62753 RPS6 29 22.91 6.83 1 1.229 n.d. n.d.
15 Secreted phosphoprotein 2, 24 kDa Q13103 SPP24 24 22.13 4.27 1 1.22 1.208 n.d.
16 Fibrinogen gamma chain P02679 FGG 52 1307.66 63.58 29 1.212 n.d. n.d.
17 Complement factor H-related protein 1 Q03591 FHR1 38 465.78 36.97 2 1.211 n.d. n.d.
18 Fibrinogen alpha chain P02671 FGA 95 2078.11 46.88 40 1.207 n.d. n.d.
19 Hemopexin P02790 HPX 52 245.23 22.73 8 1.204 n.d. n.d.
20 von Willebrand factor P04275 VWF 309 343.44 4.41 11 0.816 n.d. n.d.
21 Keratin 2 P35908 KRT2 65 288.46 11.58 6 0.814 0.723 n.d.
22 Pregnancy-zone protein P20742 PZP 164 422.01 10.86 11 0.803 n.d. n.d.
23 Apolipoprotein E P02649 APOE 36 1149.96 66.25 22 0.786 n.d. n.d.
24 Thrombospondin 1 P07996 THBS1 129 112.25 4.79 4 0.779 0.709 0.825
25 Gelsolin P06396 GSN 86 225.78 11.64 6 0.762 n.d. n.d.
26 Insulin-like growth factor-binding protein 3 P17936 IBP3 32 25.36 5.84 1 0.758 n.d. n.d.
27 Extracellular matrix protein 1 Q16610 ECM1 61 365.78 22.41 9 0.736 n.d. n.d.
28 Annexin 1 P04083 ANXA1 39 31.01 4.34 1 0.726 n.d. n.d.
29 Hyaluronoglucosaminidase 1 Q12794 HYAL1 48 40.73 5.52 1 0.657 0.716 n.d.
30 Serpin F1 P36955 PEDF 46 33.05 2.15 1 0.586 n.d. n.d.
31 Annexin A2 pseudogene 2 A6NMY6 ANXA2P2 39 30.15 4.72 1 0.357 n.d. n.d.
aFor a candidate protein, the fold change (ratio) of at least or more than 1.2, and at least or less than 0.80 in plasma content was considered and reported as
up- and downregulation, respectively. ASt, Abnormal Savda type tumours; nASt, non-Abnormal Savda type tumours; NC, normal controls; n.d. no difference (fold
change of less than 1.2 or more than 0.8); ASt/nASt, fold change of all differentially expressed proteins between ASt and nASt; ASt/NC or nASt/NC, fold change of
the same proteins between ASt and NC or nASt and NC as those differentially expressed in ASt/nASt.
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Ontology database identified most of the proteins as
potential biomarkers that had previously been described
in other studies. Among them, 17 proteins are involved in
stomach disease or neoplasm (P04083, P02649, P49327,
P02671, P02679, P06396, P10809, Q12794, P17936,
P20742, P02753, P02735, P02735, P35542, P01011,
P07996, and P04275) and 22 are potential biomarkers
for breast disease and neoplasm, in particular five proteins(P07996, P10809, P17936, Q16610, and Q12794) for breast
ductal carcinoma, one (P17936) for hereditary breast can-
cer, and one (P01011) for fibrocystic breast disease. All
proteins except one (A6NMY6) are involved in lung
disease or neoplasm, particularly 14 proteins (P01833,
P02735, P02649, P02763, P04275, P02679, P06396,
P07996, P10809, P17936, P36955, P62753, Q06033,
and Q12794) in bronchial neoplasm, three (P17936,
P02763, and P62753) in small cell lung carcinoma, and
Figure 1 The role and function of proteins associated with Abnormal Savda type tumours (ASt) in biological processes as displayed by
MetaCore™ analysis (p < 0.05). The analysis includes the function of 31 proteins described in Table 1.
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P10809, Q12794, P17936, P36955, and P62753) in non-
small cell lung carcinoma. These findings suggest that
the development of Abnormal Savda in tumour patients
is probably associated with dysregulation of a whole pro-
tein interaction network, and is mainly manifested in ab-
errant expression of potential biomarkers for malignant
tumours.
As shown in Table 1, 10 out of the 31 identified pro-
teins may distinguish ASt from nASt and NC and are
therefore important candidate biomarkers for ASt.
Figure 2 shows the potential interaction and regulation
networks associated with these proteins in cellular signal-
ling and gene expression. These proteins are localized in
the extracellular space (matrix), membrane, or cytoplasm;Acvaon eﬀect Inhibion eﬀect 
Figure 2 Network profile for protein interactions associated with 10 c
MetaCore™. The network includes THBS1, LBP, SAA1, ORM1, PIGR, SPP24, Hare involved in interactions with diverse effectors, such as
endopeptidases, matrix metalloproteinases, and phospha-
tases; and are mainly regulated by transcription factors
downstream of distinct signalling pathways.
Verification of candidate proteins as potential biomarkers
for ASt by ELISA
We further verified the results of proteomics analysis by
ELISA determination of nine out of the 10 proteins
(with the exception of KRT2) that were differentially
expressed in ASt compared with both nASt and NC
using plasma samples from 136 patients and 40 normal
controls. Statistical analysis confirmed significant upreg-
ulation of plasma SAA1, SPP24, LBP, and THBS1, and




















andidate proteins in cellular signalling and gene expression by
YAL1, FASN, KRT2, and ZNF452 as described in Table 1.
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found for ORM1 and HYAL1 (p > 0.05) (Table 2 and
Additional file 2). Importantly, the plasma levels of
SAA1, PIGR, SPP24, and FASN were also significantly
different in ASt compared with nAST (p < 0.05)
(Table 2). However, the results of these analyses were
not concordant with proteomics data in all cases. For ex-
ample, expression of PIGR and FASN was upregulated
in ASt compared with nASt (or compared with NC) ac-
cording to iTRAQ proteomics, but ELISA showed sig-
nificant downregulation of these proteins. In addition,
the ELISA analysis showed incremental differences in
the expression of some proteins, such as PIGR, ZNF
452, SPP24, and FASN, among the three groups of ASt,
nASt, and NC, whereas no difference was found for
these proteins when nASt was compared with NC by
proteomics. These discrepancies should be clarified by
future studies or intensively investigated by consulting
other reports in this field.
Discussion
Over time, Uighur medicine has developed relatively
complete medical theories, diagnostic methods, and
unique prescriptions [2,15]. However, because of a lack
of scientific interpretations, Uighur medicine has the
same shortcomings as other traditional medicines [32].Table 2 Determination of candidate proteins as potential bio
by ELISA
Plasma protein level (ng/mL)
ASt (n = 71) nASt (n = 65) NC (n =
SAA1 12.755 ± 6.990 9.468 ± 6.965 6.790 ±
PIGR 37.868 ± 14.336 45.298 ± 14.325 60.734 ±
ORM1 19.400 ± 5.557 22.217 ± 5.279 20.234 ±
ZNF452 0.758 ± 0.362 0.701 ± 0.538 1.698 ±
SPP24 2270.987 ± 304.153 2090.084 ± 264.598 1792.224
FASN 0.847 ± 0.275 1.129 ± 0.654 2.501 ±
LBP 204.220 ± 24.523 199.499 ± 46.947 11.609 ±
HYAL1 12.666 ± 5.069 11.785 ± 5.225 11.351 ±
THBS1 4.154 ± 2.641 3.366 ± 1.922 1.579 ±
ASt, nASt or NC, refer to patients with Abnormal Savda type tumours, non-Abnormal S
comparative analysis between two groups indicated, with statistical significance at p <The development of proteomics means there is the pos-
sibility that serum/plasma can eventually be established
as a biomedium for the study of tumour aetiology, drug
targets, and personalized cancer care in contemporary
medicine [33-35]. In traditional Chinese medicine, many
investigators have combined classical concepts with sys-
tems biology, in particular applying proteomics to stud-
ies of disease aetiology in association with syndromes
and multi-target effects of prescriptions [32,36-37]. Thus,
it is feasible to study the whole regulation network of pro-
tein expression that is altered in the development of differ-
ent syndromes described in Uighur medicine to reveal the
biological basis of these conditions and discover diagnostic
biomarkers. This is a holistic concept that is shared by
both systems biology and traditional medicine.
Here, we studied the profile of differentially expressed
plasma proteins among patients with tumours with
Abnormal Savda (ASt), those with tumours and other
syndromes (nASt), and healthy individuals as normal
controls (NC). Analysis of iTRAQ proteomics data re-
vealed upregulation of 34 proteins and downregulation
of 26 proteins in both ASt and nASt compared with NC.
Since ASt and nASt are both tumour conditions, these
results suggest that ASt and nASt may differ from NC in
the shared regulatory networks of protein expression in-
volved in carcinogenesis. Subsequent analysis identifiedmarkers for Abnormal Savda on whole blood (plasma)
ANOVA test (p value)
40) F P ASt/nASt ASt/NC nASt/NC
4.529 5.645 .035 .002 .150
.005
11.913 13.249 .038 .000 .001
.000
2.940 2.309 .037 .589 .206
.106
1.112 16.84 .724 .004 .003
.000
± 266.44 15.057 .018 .000 .001
.000
1.114 34.913 .015 .000 .000
.000
4.454 146.833 .624 .000 .000
.000
5.330 4.71 .486 .368 .769
.626
1.100 7.777 .148 .000 .008
.001
avda type tumours, or normal controls, respectively; ASt/nASt, ASt/NC, nASt/NC,
0.05.
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pared with nASt. Most of these proteins are differentially
expressed between ASt and nASt in each of three cancer
types (lung, breast, or gastric cancer), suggesting that
the altered expression of these proteins is associated
with Abnormal Savda syndrome. According to bioinfor-
matics analysis, these proteins are mainly localized in
the extracellular matrix or cytoplasm, and are involved
in many signalling pathways through binding to other
proteins or in the inhibition of endopeptidases or phos-
pholipases. Moreover, most of the proteins are known
biomarkers for diseases or neoplasms of the stomach,
lung, and breast. Thus, the differentially expressed pro-
teins between ASt and nASt are potential biomarkers for
malignant tumours associated with Abnormal Savda.
Among these 31 proteins, only 10 proteins showed dif-
ferential expression that quantitatively distinguished ASt
from NC by iTRAQ proteomics. This was partially con-
firmed by ELISA analysis, which showed that expression
of SAA1, SPP24, LBP, THBS1, PIGR, ZNF452, and FASN
was significantly altered in the plasma of patients with
ASt compared with NC plasma. Importantly, there were
significant differences in the expression of SAA1, SPP24,
PIGR, and FASN between ASt and nASt and between
ASt and NC. Of these proteins, SAA1 is an acute-phase
protein that is produced and secreted predominantly by
the liver, and associates with high-density lipoprotein
(HDL) particles. Plasma SAA1 level is a known bio-
marker for tumour malignancy, host response, and
chemotherapy resistance [38-42]. SAA1 protein expres-
sion is upregulated in many common cancers, including
lung, ovarian, renal, uterine, and nasopharyngeal cancer
[43,44]. High levels of circulating SAA1 are mainly in-
duced by the binding of activated STAT3 and NF-kB
transcription factors upon stimulation by inflammation-
associated cytokines IL-1 and IL6, and to a lesser extent
by the synthesis of this protein in metastatic cells
[45-47]. These findings are consistent with the results of
our study showing that increased SAA1 expression in
patients with malignant tumours is closely associated
with Abnormal Savda. Although there were discrepan-
cies in our data for altered expression of PIGR and
FASN between iTRAQ and ELISA analysis, other studies
have reported the association of both PIGR and FASN
expression with tumourigenesis and implied a possible
association with Abnormal Savda. PIGR is expressed on
mucosal epithelial cells and transports polymeric im-
munoglobulin A (pIgA) produced by mucosal B cells to
the mucosal surface where secretory immunoglobulin A
(SIgA) excludes multitudes of dietary, environmental,
and microbial antigens to form an initial defence against
infection [48]. Consistent with our data from ELISA ana-
lysis, downregulation of pIgR is associated with the de-
velopment of most lung cancers, adenocarcinomas ofdistal oesophagus and gastro-oesophageal junction, and
hepatocellular carcinoma [49-52]. FASN is the key en-
zyme required for de novo synthesis of fatty acids [53].
The results of iTRAQ proteomics in this study are con-
cordant with previous reports that elevated FASN ex-
pression is associated with cancer progression, higher
risk of recurrence, shorter survival, and resistance to an-
ticancer therapy of several human cancers, including
breast, prostate, kidney, endometrium, colon, lung, and
gastric cancer [53-56]. Secreted phosphoprotein 24 kD
(SPP24) is a bone matrix protein that is expressed pri-
marily in the liver and bone and binds to and affects the
activity of bone morphogenetic proteins (BMPs) [57,58].
SPP24 appears to reduce the growth of tumour cells by
binding to both BMP-2 and TGF-β in vitro, but whether
plasma SPP24 is upregulated during tumourigenesis
in vivo is not currently known [59].
Although the differences in plasma levels of LBP,
THBS1, or ZNF452 between ASt and nASt were not
confirmed by ELISA, the data from iTRAQ proteomics
implicate a role of these proteins to some extent in the
development of Abnormal Savda. LBP is an acute-phase
protein that initiates an immune response after recogni-
tion of bacterial LPS, and mutations in LBP can impair
innate immunity [60]. LBP may inhibit TLR2-dependent
production of inflammatory cytokines [61]. In conditions
of obesity and coronary artery disease LBP expression is
targeted by LXRs from macrophages, and serum LBP
may serve as an important marker for atherosclerosis.
However, the upregulation of circulating LBP in associ-
ation with tumour malignancy has not been reported
previously. THBS1 (TSP1) is a large matricellular glyco-
protein that is secreted by many cell types and physically
interacts with a variety of ligands during acute and sub-
acute processes [62,63]. The role of THBS1 in tumour
growth and metastasis is complicated by its controversial
function as a cancer inhibitor or promoter [64]. THBS1
expression is downregulated in advanced non-small cell
lung cancer and lymph node metastasis and in breast
cancer patients positive for both oestrogen and proges-
terone receptors [65,66]. In contrast, overexpression of
THBS1 in stromal myofibroblasts is associated with
tumour growth and nodal metastasis in gastric carcin-
oma, and may promote tumour cell invasion via upregu-
lation of MMP-9 expression by endothelial cells [67,68].
THBS1 secreted by CD4+ and CD8+ T cells can nega-
tively regulate angiogenesis in a tumour-bearing mice
model [69]. In another study, we demonstrated the up-
regulation of plasma THBS1 in patients with Abnormal
Savda in response to treatment with the prescription for
Abnormal Savda, suggesting that downregulation of
THBS1 may be associated with Abnormal Savda [70].
There are a limited number of studies on the role of
ZNF452 in the plasma and tumour tissue of patients in
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protein in ASt and nASt compared with controls may
provide a novel perspective on the link between cancer
progression and Abnormal Savda.
The limitations of this study include verification in a
relatively small number of samples from patients (136
cases) and controls (40 cases), the diversity of tumour
origin or types, and the restriction of breast cancer to fe-
males. Therefore, future validation on a relatively large
number of samples is required to establish a standard
for the clinical diagnosis of Abnormal Savda among pa-
tients with malignant tumours. In addition, independent
studies on patients with other tumour types are needed
to verify the findings of this study.
Conclusions
This is the first study of malignant tumours as a com-
plex disease in association with Abnormal Savda at a
proteomics level. Our data confirm plasma SAA1, PIGR,
SPP24, FASN, and possibly THBS1 as potential bio-
markers that are common to different types of malignant
tumours and associated with Abnormal Savda. These
findings may uncover the mechanisms of tumourigenesis
associated with Abnormal Savda, and will contribute
to scientific interpretation and standard application of
Uighur medicine in the clinical diagnosis and therapy of
malignant tumours.
The official terminology ‘abnormal Hilit’ is used in
Uighur medicine to describe a syndrome. In this sense,
‘Abnormal Savda’ is interchangeable with ‘Abnormal
Savda syndrome’.
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